Clinical trials: Corticosteroid Injection
Asthma
A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)
This study is a placebo-controlled study with 8-weeks of double-blind treatment of mometasone furoate dry powder inhaler (MF DPI) 200 mcg twice daily (BID) using two different inhalers, preceded by the Screening Period and by 2…
- Trial name
- NCT00521599
- Testing
- Mometasone furoate dry powder inhaler
- Volunteers
- 672 people
- Sponsor
- Organon and Co
Asthma
Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids
The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical…
- Trial name
- NCT01332344
- Testing
- Fluticasone propionate/salmeterol combination, Inhaled corticosteroids
- Volunteers
- 5,180 people
- Sponsor
- GlaxoSmithKline
Asthma
Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation
This is an open-label, five- period, cross-over, randomized, single dose, single centre study in healthy subjects. This is the second clinical study for the UD-DPI.
- Trial name
- NCT02218723
- Testing
- FF UD-DPI, FF ELLIPTA DPI
- Where
- 2 sites in Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
This study aims to assess the effect on total systemic exposure and to characterize exposure BGF MDI HFO with a spacer compared to without a spacer; also, to demonstrate that total systemic exposure of BGF when administered as…
- Trial name
- NCT06297668
- Testing
- Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Asthma in Children
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.
- Trial name
- NCT04450108
- Testing
- Vivatmo pro FeNO Test
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Bosch Healthcare Solutions GmbH
Crohn's Disease
Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease
The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease.
- Trial name
- COSPAR1 (NCT00349752)
- Testing
- certolizumab pegol 400 mg
- Where
- 68 sites in United States, Canada and 1 more
- Volunteers
- 174 people
- Sponsor
- UCB Pharma
Asthma
AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma
The goal of treatment with AICS is weaning from oral corticosteroids, i.e. a reduction of the oral corticosteroid dose. An anticipated treatment benefit of AICS is a reduction of oral corticosteroid dose and stability/improvement…
- Trial name
- NCT01200108
- Testing
- Budesonide
- Where
- 24 sites in Germany, Poland and 1 more
- Sponsor
- Activaero GmbH
Lumbosacral Radicular Pain
Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain.
- Trial name
- NCT03372161
- Testing
- SP-102
- Where
- 37 sites in United States
- Volunteers
- 401 people
- Sponsor
- Scilex Pharmaceuticals, Inc.
Atopic Dermatitis
Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis
Topical steroid use may lead to skin deterioration and spider veins. This study will examine long-term management of atopic dermatitis (AD) over 12 months with pimecrolimus cream 1% and its effect on skin reconstitution of…
- Trial name
- NCT00367393
- Testing
- Pimecrolimus cream 1%
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Novartis
Stenosing Tenosynovitis
Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger
The proposed study aims to investigate whether amniotic fluid injections are a better alternative to corticosteroid injections as a conservative treatment for stenosing tenosynovitis.
- Trial name
- NCT03583151
- Testing
- Amniotic fluid injection, Steroid injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- J&M Shuler
Asthma
Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function
The proposed study is designed to investigate the pharmacokinetics, pharmacodynamics (as measured by serum cortisol) and safety of GW685698X in subjects with moderate hepatic impairment and in healthy subjects following a single…
- Trial name
- NCT00419237
- Testing
- GW685698X
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled…
- Trial name
- NCT01460862
- Sponsor
- Novartis Pharmaceuticals
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when…
- Trial name
- NCT02139644
- Testing
- FS MDPI, Fp MDPI, albuterol/salbutamol
- Where
- 140 sites in United States, Canada and 6 more
- Volunteers
- 787 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Atopic Dermatitis
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of…
- Trial name
- NCT03539601
- Testing
- Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%
- Where
- 32 sites in United States, Germany and 5 more
- Volunteers
- 237 people
- Sponsor
- Pfizer
Dermatitis, Atopic, Eczema, Atopic
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination…
- Trial name
- NCT06554847
- Testing
- 611, Topical corticosteroid
- Where
- 3 sites in China
- Volunteers
- 417 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Asthma
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma who are receiving oral corticosteroids with or without additional asthma controller…
- Trial name
- WAYFINDER (NCT05274815)
- Testing
- Tezepelumab
- Where
- 77 sites in United States, Argentina and 9 more
- Volunteers
- 305 people
- Sponsor
- AstraZeneca
Bilateral Knee Osteoarthritis
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
This is a randomized, open-label, parallel group study to compare systemic exposure of triamcinolone acetonide following administration into both knees of either FX006 or TAcs.
- Trial name
- NCT03378076
- Testing
- FX006 32 mg, TAcs 40 mg
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Non-Segmental Vitiligo (NSV)
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world…
- Trial name
- NCT07673640
- Testing
- 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- ShanShan Li